A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Benjamin Ory and Leif W. Ellisen * Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA Received: March 9, 2011; Accepted: March 23, 2011; Published: March 23, 2011; Keywords: p63, p73, microRNA, apoptosis, cisplatin, squamous cell carcinoma, triple-negative breast cancer, chemosensitivity Correspondence: Leif W. Ellisen, e-mail: // // Abstract The p53 family transcription factors p53, p63 and p73 make diverse contributions in development and cancer. Mutation or deletion of p53 is observed in the majority of human cancers. In contrast, p63 and p73 are not lost in cancer but mediate distinct genetic roles in normal and tumor-specific contexts: p73 promotes genome stability and mediates chemosensitivity, while p63 largely lacks these p53-like functions and instead promotes proliferation and cell survival. We recently uncovered a mechanism which maintains p63/p73 homeostasis within the epithelium through direct transcriptional regulation of microRNAs (miRs). We discovered that several of the top p63-regulated miRs target p73 for inhibition, including miR-193a-5p, a direct p63/p73 transcriptional target which is repressed by p63 and activated by p73 both in vitro and in vivo . The resulting feed-forward circuit involving p63, miR-193a-5p and p73 controls p73 levels, cell viability and DNA damage susceptibility in certain cancers including squamous cell carcinoma. Here, we discuss the evolutionary implications of this regulatory circuit, which may point to a general mechanism of miR-mediated cross-talk within transcription factor gene families. Additionally, we suggest that inducible chemoresistance mediated by this miR-dependent mechanism might be an attractive target for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“Loss of p53 transcription factor function in cancer reflects the diverse contribution of this protein to the DNA damage response, cell cycle regulation, cell survival and many other functions [1].”
BackgroundTransactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010 · cited 1×
“In particular, miR-34a is a direct transcriptional target of p53 which contributes to p53dependent functions through interaction with p53-regulated mRNAs [15-17].”
Backgroundp63 is a p53 homologue required for limb and epidermal morphogenesis
Mills, A. A., Zheng, B., Wang, X.-J., Vogel, H., Roop, D. R., & Bradley, A. (1999) · Nature · doi:10.1038/19531 · Cited by 1,988
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
A skin microRNA promotes differentiation by repressing ‘stemness’
Yi, R., Poy, M. N., Stoffel, M., & Fuchs, E. (2008) · Nature · doi:10.1038/nature06642 · Cited by 790 · cited 1×
“TAp63 isoforms function as metastasis suppressors in certain cancers in part through regulation of a miR-dependent program [20], and at least one miR has been identified to control p63 itself and to modulate its developmental role [21].”
BackgroundMicroRNA-Mediated Feedback and Feedforward Loops Are Recurrent Network Motifs in Mammals
Tsang, J., Zhu, J., & van Oudenaarden, A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.018 · Cited by 740 · cited 2×
“from proliferation to growth arrest or cell death) [23].”
BackgroundCanalization of development by microRNAs
Hornstein, E., & Shomron, N. (2006) · Nature Genetics · doi:10.1038/ng1803 · Cited by 578 · cited 1×
“Indeed, the stability provided by miR-mediated circuits has been proposed to contribute to “evolvability” by buffering the phenotypic consequences of genetic variation [28].”
Background
Cited by
MicroRNA Expression Characterizes Oligometastasis(es)
Lussier, Y. A., Xing, H. R., Salama, J. K., Khodarev, N. N., Huang, Y., Zhang, Q., Khan, S. A., Yang, X., Hasselle, M. D., Darga, T. E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028650 · Cited by 281
microRNA-1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers
Nohata, N., Hanazawa, T., Enokida, H., & Seki, N. (2012) · Oncotarget · doi:10.18632/oncotarget.424 · Cited by 253
Li, H., & Yang, B. B. (2012) · Oncotarget · doi:10.18632/oncotarget.810 · Cited by 117
Azmi, A. S., Banerjee, S., Ali, S., Wang, Z., Bao, B., Beck, F. W. J., Maitah, M., Choi, M., Shields, T. F., Philip, P. A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.269 · Cited by 48
“Additionally, a number of critical networks including microRNA circuits have been shown to crosstalk with p53 family members p63 and p73 that ultimately governs therapeutic efficacy of drug treatment [30].”
BackgroundThe emerging functions of the p53-miRNA network in stem cell biology
Lin, C.-P., Choi, Y. J., Hicks, G. G., & He, L. (2012) · Cell Cycle · doi:10.4161/cc.20207 · Cited by 38
Metadata
- Authors
- Ory, B., & Ellisen, L. W.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2011-03-23
- Volume
- 2
- Issue
- 3
- Pages
- 259-264
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2101956922
- Cited by
- 47
- References
- 7
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.